Taylor & Francis

Human Vaccines & Immunotherapeutics Template

Write in a clean editor, then format for Human Vaccines & Immunotherapeutics in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

About the Human Vaccines & Immunotherapeutics format

Human Vaccines & Immunotherapeutics is a peer-reviewed journal published by Taylor & Francis, covering Vaccine Coverage and Hesitancy, Influenza Virus Research Studies, SARS-CoV-2 and COVID-19 Research.

PublisherTaylor & Francis
Reference styleAuthor–year (Chicago, T&F)
Author–year — (Smith, 2023) in the text
Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Human Vaccines & Immunotherapeutics 12 (3): 45–58.

Formats any DOI in Human Vaccines & Immunotherapeutics style. No sign-up.

Publishes research inVaccine Coverage and Hesitancy Influenza Virus Research Studies SARS-CoV-2 and COVID-19 Research Respiratory viral infections research Hepatitis B Virus Studies
ISSN2164-5515
Citation impact (2-yr)3.96
h-index130
i10-index3,700
Total citations152,157
Article processing charge$3,175
Open accessYes
Top institutions publishing hereGlaxoSmithKline (Belgium)
Journal websitewww.tandfonline.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in Human Vaccines & Immunotherapeutics per year

471
2014
469
2015
465
2016
430
2017
429
2018
437
2019
486
2020
641
2021
559
2022
522
2023
548
2024
549
2025

Citation impact of Human Vaccines & Immunotherapeutics by publication year

13.7K
2014
13K
2015
13.6K
2016
12.9K
2017
12.6K
2018
11.6K
2019
14.4K
2020
13.2K
2021
9.2K
2022
5.7K
2023
3.8K
2024
1.5K
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in Human Vaccines & Immunotherapeutics

Vaccine hesitancy

Ève Dubé, Caroline Laberge, Maryse Guay et al. · 11 Jul 2013

Despite being recognized as one of the most successful public health measures, vaccination is perceived as unsafe and unnecessary by a growing number of individuals. Lack of confidence in vaccines is now considered a threat to the success of vaccination programs. Vaccine hesitancy is believed to be responsible for decreasing vaccine coverage and an increasing…

2,210 citations Cite SaveGo to paper →
Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases

Neha Puri, Eric A. Coomes, Hourmazd Haghbayan et al. · 21 Jul 2020

Despite major advances in vaccination over the past century, resurgence of vaccine-preventable illnesses has led the World Health Organization to identify vaccine hesitancy as a major threat to global health. Vaccine hesitancy may be fueled by health information obtained from a variety of sources, including new media such as the Internet and social media platforms.…

1,203 citations Cite SaveGo to paper →
The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay

Li Ping Wong, Haridah Alias, Pooi-Fong Wong et al. · 30 Jul 2020

BACKGROUND: The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations. METHODS: A cross-sectional survey was conducted from 3 to 12 April 2020. The…

COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey

Susan M. Sherman, Louise Smith, Julius Sim et al. · 26 Nov 2020

To investigate factors associated with intention to be vaccinated against COVID-19 we conducted a cross-sectional survey of 1,500 UK adults, recruited from an existing online research panel. Data were collected between 14th and 17th July 2020. We used linear regression analyses to investigate associations between intention to be vaccinated for COVID-19 "when a vaccine becomes…

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

Kuldeep Dhama, Khan Sharun, Ruchi Tiwari et al. · 18 Mar 2020

studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt…

Human Vaccines & Immunotherapeutics template — frequently asked questions

How do I write a paper in the Human Vaccines & Immunotherapeutics format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the Human Vaccines & Immunotherapeutics template. When you export, DocuGuru compiles the paper into the official Taylor & Francis format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does Human Vaccines & Immunotherapeutics use?
Human Vaccines & Immunotherapeutics uses Author–year (Chicago, T&F) references, shown as author–year markers such as (Smith, 2023) in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Human Vaccines & Immunotherapeutics 12 (3): 45–58.
Do I need to know LaTeX to submit to Human Vaccines & Immunotherapeutics?
No. DocuGuru generates the interact LaTeX class and compiles the PDF for you in the background, so you get a Taylor & Francis-ready Human Vaccines & Immunotherapeutics document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the Human Vaccines & Immunotherapeutics template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the Human Vaccines & Immunotherapeutics format with correct headings, figures, tables, and author–year citations.
Who publishes Human Vaccines & Immunotherapeutics?
Human Vaccines & Immunotherapeutics is a multidisciplinary journal published by Taylor & Francis. DocuGuru's Human Vaccines & Immunotherapeutics template matches Taylor & Francis's official submission format.
Can I export a submission-ready Human Vaccines & Immunotherapeutics PDF?
Yes — DocuGuru produces a PDF built with the official Human Vaccines & Immunotherapeutics template (the interact class) that is ready to submit to Taylor & Francis, together with the matching LaTeX source files.
How much does the Human Vaccines & Immunotherapeutics template cost?
You can start writing in the Human Vaccines & Immunotherapeutics template for free. Exporting the final submission-ready Human Vaccines & Immunotherapeutics PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the Human Vaccines & Immunotherapeutics template